- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL awaits FDA extension of breast PMA
ATL chairman and CEO Dennis Fill this month said he expects theFood and Drug Administration to approve within the next severalweeks the use of the company's flagship HDI 3000 scanner for differentiatingmalignant from benign solid breast lesions. ATL, of
ATL chairman and CEO Dennis Fill this month said he expects the
Food and Drug Administration to approve within the next several
weeks the use of the company's flagship HDI 3000 scanner for differentiating
malignant from benign solid breast lesions. ATL, of Bothell, WA,
already has FDA approval to differentiate solid breast lesions
using its older Ultramark 9 HDI scanner, and filed a supplemental
premarket approval application with the agency to extend the technique
to HDI 3000 (SCAN 4/24/96). Fill made the comments during a presentation
at the Bear Stearns Health Care Conference in New York City.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
